---
title: "Pulse Biosciences slips despite Q4 beat after deal to sell shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276460583.md"
description: "Pulse Biosciences (PLSE) shares fell on Friday despite exceeding Q4 2025 financial forecasts. The decline followed the announcement of an agreement with TD Securities to sell up to ~$60M worth of shares. The equity distribution agreement allows Pulse to offer approximately ~$59.98M shares of its common stock over time."
datetime: "2026-02-20T15:37:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276460583.md)
  - [en](https://longbridge.com/en/news/276460583.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276460583.md)
---

# Pulse Biosciences slips despite Q4 beat after deal to sell shares


### Related Stocks

- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PLSE.US](https://longbridge.com/en/quote/PLSE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study](https://longbridge.com/en/news/281891382.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)
- [Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | AVTBF Stock News](https://longbridge.com/en/news/282741678.md)
- [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)